NCT02472366已完成4 期
A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Changes in Best Corrected Visual Acuity From Baseline
研究概览
简要总结
A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients insufficiently responsive to available therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥18 years of age, of either sex that have signed informed consent / been well informed by the treating physician.
- •DME based on investigator's clinical evaluation and demonstrated using fundoscopic photography and spectral domain OCT.
- •Mean central foveal thickness (central subfield thickness) ≥350 microns in the study eye as measured using spectral domain OCT.
- •Vision impairment (20/60 to 20/400 using Snellen visual acuity equivalent) related to DME.
- •Previous treatment in the study eye with laser photocoagulation for DME, including focal/grid and pan-retinal, at least 3 months prior to the screening visit and ≥3 monthly anti-VEGF treatments (group 1).
- •Previous treatment in the study eye with laser photocoagulation for DME at least 3 months prior to the screening visit (group 2) and treatment with an intraocular anti-VEGF therapy not possible.
- •Patients considered as insufficiently responsive to prior therapy for DME, as defined by the study physician.
排除标准
- •IOP >21 mmHg at screening in the study eye.
- •Historical rise in IOP >25 mmHg following treatment with an intravitreal corticosteroid in the study eye.
- •Use of ≥2 IOP-lowering medications to control IOP at screening in the study eye.
- •Patients that have vitreomacular traction in DME and opaque media in the study eye.
- •Patients with severe proliferative diabetic retinopathy requiring pan retinal photocoagulation in the study eye.
- •Pregnant or breastfeeding.
- •Patients diagnosed with active angiographic central vein ischaemia prior to screening in the study eye.
- •Patients that have received pan retinal photocoagulation or undergone cataract surgery in the 3 months prior to the study start date in the study eye.
- •Patients with contraindications according to the current SPC:
- •The presence of pre-existing glaucoma.
- •Active or suspected ocular or periocular infection.
- •The patient is hypersensitive to the active agent or to one of the excipients.
研究组 & 干预措施
laser
Other
laser with or without prior history of intraocular corticosteroid therapy
干预措施: ILUVIEN (Drug)
laser and anti-VEGF
Other
laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
干预措施: ILUVIEN (Drug)
结局指标
主要结局
Changes in Best Corrected Visual Acuity From Baseline
时间窗: Change from Baseline to 12 months post ILUVIEN administration
Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.
次要结局
- Changes in Intraocular Pressure (IOP)(Change from Baseline to 12 months post ILUVIEN administration)
- Changes in Central Subfield Thickness(Change from Baseline to 12 months post ILUVIEN administration)
- Changes in Macular Volume(Change from Baseline to 12 months post ILUVIEN administration)
研究者
相似试验
终止
不适用
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available TherapiesDiabetic Macular Edema (DME)NCT02080091Alimera Sciences25
已完成
4 期
A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema PatientsDiabetic Macular EdemaNCT02359526Association for Innovation and Biomedical Research on Light and Image12
已完成
3 期
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DMEDiabetic Macular EdemaNCT02262260Novartis Pharmaceuticals87
进行中（未招募）
不适用
Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma - Basket 1Patients with Desmoid Tumor and ChondrosarcomaMedDRA version: 9.1Level: LLTClassification code 10039491Term: SarcomaEUCTR2006-006446-33-ITITALIAN SARCOMA GROUP
已完成
3 期
Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIgDemyelinating PolyneuropathyNCT01349270Centre Hospitalier Universitaire de Saint Etienne40